[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CO6710903A2 - Un anticuerpo que reconoce y se une específicamente con un fosfo-epítope en la proteína tau de mamífero o en uno de sus fragmentos y una composición comprendiendo el mismo - Google Patents

Un anticuerpo que reconoce y se une específicamente con un fosfo-epítope en la proteína tau de mamífero o en uno de sus fragmentos y una composición comprendiendo el mismo

Info

Publication number
CO6710903A2
CO6710903A2 CO13089514A CO13089514A CO6710903A2 CO 6710903 A2 CO6710903 A2 CO 6710903A2 CO 13089514 A CO13089514 A CO 13089514A CO 13089514 A CO13089514 A CO 13089514A CO 6710903 A2 CO6710903 A2 CO 6710903A2
Authority
CO
Colombia
Prior art keywords
tau protein
phospho
epitope
binds
fragments
Prior art date
Application number
CO13089514A
Other languages
English (en)
Inventor
Andrea Pfeifer
Andreas Muhs
Leuven Fred Van
Maria Pihlgren
Oskar Adolfsson
Original Assignee
Ac Immune Sa
Univ Leuven Kath
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44947048&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6710903(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ac Immune Sa, Univ Leuven Kath filed Critical Ac Immune Sa
Publication of CO6710903A2 publication Critical patent/CO6710903A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)

Abstract

La presente invención se refiere a métodos y composiciones para el uso terapéutico y de diagnóstico en el tratamiento de enfermedades y trastornos que son causados por ovillos neurofibrilares o están asociados con ellos. En particular, la invención se refiere a anticuerpos, que específicamente reconocen y se unen a conformadores de proteína tau patológicos fosforilados y con métodos y composiciones que incluyen dichos anticuerpos para el uso terapéutico y diagnóstico en el tratamiento de tauopatías entre las que encuentra la enfermedad de Alzheimer (EA).
CO13089514A 2010-10-07 2013-04-05 Un anticuerpo que reconoce y se une específicamente con un fosfo-epítope en la proteína tau de mamífero o en uno de sus fragmentos y una composición comprendiendo el mismo CO6710903A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10186810 2010-10-07
EP11174248 2011-07-15

Publications (1)

Publication Number Publication Date
CO6710903A2 true CO6710903A2 (es) 2013-07-15

Family

ID=44947048

Family Applications (1)

Application Number Title Priority Date Filing Date
CO13089514A CO6710903A2 (es) 2010-10-07 2013-04-05 Un anticuerpo que reconoce y se une específicamente con un fosfo-epítope en la proteína tau de mamífero o en uno de sus fragmentos y una composición comprendiendo el mismo

Country Status (28)

Country Link
US (2) US9304138B2 (es)
EP (2) EP2625198B1 (es)
JP (2) JP6371526B2 (es)
KR (1) KR101988672B1 (es)
CN (1) CN103502272B (es)
AR (1) AR085198A1 (es)
AU (1) AU2011311516B2 (es)
BR (1) BR112013008333B1 (es)
CA (1) CA2812865C (es)
CL (1) CL2013000951A1 (es)
CO (1) CO6710903A2 (es)
CR (1) CR20130160A (es)
DK (1) DK2625198T3 (es)
EC (1) ECSP13012609A (es)
ES (1) ES2548686T3 (es)
HK (2) HK1187928A1 (es)
HU (1) HUE027649T2 (es)
IL (1) IL225568A (es)
MX (1) MX338421B (es)
MY (1) MY164376A (es)
PE (1) PE20140218A1 (es)
PL (1) PL2625198T3 (es)
RU (1) RU2603078C2 (es)
SG (1) SG189136A1 (es)
SI (1) SI2625198T1 (es)
TW (1) TW201216985A (es)
WO (1) WO2012045882A2 (es)
ZA (1) ZA201302432B (es)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10266585B2 (en) * 2009-08-28 2019-04-23 The Board Of Regents Of The Univerity Of Texas System Methods of treating brain injury
US10130697B2 (en) 2010-03-23 2018-11-20 Wisconsin Alumni Research Foundation (Warf) Vaccines comprising mutant attenuated influenza viruses
JP6371526B2 (ja) * 2010-10-07 2018-08-08 エーシー イミューン エス．エー． タウを認識するリン酸化部位特異的抗体
NZ609984A (en) 2010-10-11 2015-05-29 Biogen Idec Internat Neuroscience Gmbh Human anti-tau antibodies
ES2714692T3 (es) 2011-01-31 2019-05-29 Tau Bio Logic Corp Tratamiento de tauopatías
GB201112056D0 (en) 2011-07-14 2011-08-31 Univ Leuven Kath Antibodies
US10813630B2 (en) 2011-08-09 2020-10-27 Corquest Medical, Inc. Closure system for atrial wall
US10307167B2 (en) 2012-12-14 2019-06-04 Corquest Medical, Inc. Assembly and method for left atrial appendage occlusion
US10314594B2 (en) 2012-12-14 2019-06-11 Corquest Medical, Inc. Assembly and method for left atrial appendage occlusion
KR101981351B1 (ko) * 2011-10-07 2019-09-02 에이씨 이뮨 에스.에이. 타우를 인식하는 포스포특이적 항체
NZ626269A (en) * 2011-12-20 2016-06-24 Janssen Biotech Inc Anti-phf-tau antibodies and their uses
JP6293731B2 (ja) * 2012-04-05 2018-03-14 エーシー イミューン エス．エー． ヒト化タウ抗体
KR20200013072A (ko) * 2012-07-03 2020-02-05 워싱턴 유니버시티 Tau에 대한 항체
WO2014016737A1 (en) * 2012-07-24 2014-01-30 Pfizer Inc. Novel chicken monoclonal antibodies against human phosphorylated tau and uses thereof
SG11201500888SA (en) 2012-08-16 2015-03-30 Ipierian Inc Methods of treating a tauopathy
US12024568B2 (en) 2012-09-13 2024-07-02 Cornell University Treatment of brain cancers using central nervous system mediated gene transfer of monoclonal antibodies
US20140142689A1 (en) 2012-11-21 2014-05-22 Didier De Canniere Device and method of treating heart valve malfunction
CA2896066C (en) * 2012-12-21 2022-07-12 Biogen Ma Inc. Human anti-tau antibodies
US8980270B2 (en) 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
KR102233349B1 (ko) * 2013-03-15 2021-03-31 에이씨 이뮨 에스.에이. 항-타우(tau) 항체 및 사용 방법
SG10201708143QA (en) 2013-06-06 2017-11-29 Pierre Fabre Medicament Anti-c10orf54 antibodies and uses thereof
GB201312226D0 (en) * 2013-07-08 2013-08-21 Adx Neurosciences Improved antibodies
US9566443B2 (en) 2013-11-26 2017-02-14 Corquest Medical, Inc. System for treating heart valve malfunction including mitral regurgitation
EA038994B1 (ru) * 2013-11-27 2021-11-18 Айпириэн, Инк. Способы лечения таупатии
CA2932958A1 (en) 2013-12-20 2015-06-25 F. Hoffmann-La Roche Ag Humanized anti-tau(ps422) antibodies and methods of use
NZ630610A (en) 2014-02-14 2019-05-31 Ipierian Inc Tau peptides, anti-tau antibodies, and methods of use thereof
WO2015196150A2 (en) 2014-06-20 2015-12-23 Wisconsin Alumni Research Foundation (Warf) Mutations that confer genetic stability to additional genes in influenza viruses
AR100978A1 (es) 2014-06-26 2016-11-16 Hoffmann La Roche LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS
TW202136296A (zh) 2014-06-27 2021-10-01 美商Ｃ２Ｎ醫療診斷有限責任公司 人類化抗-tau抗體
WO2016054247A1 (en) 2014-09-30 2016-04-07 Washington University Tau kinetic measurements
SI3221349T1 (sl) * 2014-11-19 2021-02-26 Axon Neuroscience Se Humanizirano tau protitelo pri alzheimerjevi bolezni
US10842626B2 (en) 2014-12-09 2020-11-24 Didier De Canniere Intracardiac device to correct mitral regurgitation
AR103713A1 (es) 2015-02-26 2017-05-31 Lilly Co Eli Anticuerpos contra tau y sus usos
PE20180317A1 (es) 2015-06-05 2018-02-09 Genentech Inc Anticuerpos anti-tau y metodos de uso
CN113929779A (zh) 2015-06-24 2022-01-14 豪夫迈·罗氏有限公司 人源化的抗-Tau(pS422)抗体和使用方法
CA2991451A1 (en) 2015-07-06 2017-01-12 Ucb Biopharma Sprl Tau-binding antibodies
JO3711B1 (ar) 2015-07-13 2021-01-31 H Lundbeck As أجسام مضادة محددة لبروتين تاو وطرق استعمالها
US10358503B2 (en) 2015-08-13 2019-07-23 New York University Antibody-based molecules selective for the {P}Ser404 epitope of Tau and their uses in the diagnosis and treatment of tauopathy
ES2862427T3 (es) * 2016-07-12 2021-10-07 H Lundbeck As Anticuerpos específicos para tau hiperfosforilada y métodos de uso de los mismos
WO2018031361A2 (en) 2016-08-09 2018-02-15 Eli Lilly And Company Combination therapy
JP2020511937A (ja) 2016-12-07 2020-04-23 ジェネンテック， インコーポレイテッド 抗ｔａｕ抗体及び使用方法
JP7193457B2 (ja) * 2016-12-07 2022-12-20 ジェネンテック， インコーポレイテッド 抗ｔａｕ抗体及び使用方法
CN110267985B (zh) * 2017-01-04 2023-05-23 H.隆德贝克有限公司 用于治疗眼科疾病的特异性针对过度磷酸化τ蛋白的抗体
JP2020508054A (ja) 2017-02-17 2020-03-19 デナリ セラピューティクス インコーポレイテッドＤｅｎａｌｉ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 抗タウ抗体及びその使用方法
JP2018139530A (ja) 2017-02-27 2018-09-13 帝人ファーマ株式会社 認知症治療又は予防のためのヒト化抗体及びその製造方法、並びにそれを用いた認知症治療剤又は予防剤
EA039569B1 (ru) * 2017-03-14 2022-02-11 Х. Лундбекк А/С Антитела, специфичные к гиперфосфорилированному тау-белку, и способы их применения
JOP20180021A1 (ar) 2017-03-16 2019-01-30 Janssen Biotech Inc الأجسام المضادة لتكتلات خيوط بروتين تاو (tau) الحلزونية المزدوجة واستخداماتها
WO2018217630A1 (en) * 2017-05-21 2018-11-29 University Of Tennessee Research Foundation Methods and compositions for targeting tissue lesions
KR20200058480A (ko) 2017-10-16 2020-05-27 에자이 알앤드디 매니지먼트 가부시키가이샤 항-타우 항체 및 그의 용도
CN111698937A (zh) * 2017-11-28 2020-09-22 国立大学法人三重大学 检测方法
WO2020028141A1 (en) 2018-07-31 2020-02-06 Eli Lilly And Company Combination therapy
US12116415B2 (en) * 2018-10-09 2024-10-15 Single Cell Technology, Inc. Anti-BCMA antibodies
AU2018446059A1 (en) * 2018-10-17 2021-05-20 The University Of Queensland Methods and compositions for treating tauopathies
EP3877399A4 (en) 2018-11-06 2022-10-19 Alsatech, Inc. CELL-BASED GENE THERAPY FOR NEURODEGENERATIVE DISEASES
JP2022522112A (ja) 2019-02-08 2022-04-14 ウィスコンシン アルムニ リサーチ ファンデイション ヒト化細胞系
CA3135170A1 (en) 2019-04-05 2020-10-08 Tauc3 Biologics Limited Anti-tauc3 antibodies and uses thereof
MX2021012488A (es) * 2019-04-12 2021-11-12 Phanes Therapeutics Inc Receptores de antigeno quimerico del receptor 1 anti-folato humanizado y usos de los mismos.
WO2020223699A1 (en) 2019-05-01 2020-11-05 Wisconsin Alumni Research Foundation (Warf) Improved influenza virus replication for vaccine development
CN110028583B (zh) * 2019-05-07 2020-09-11 温州医科大学 抗Tau抗体及其在治疗阿尔茨海默病、创伤性脑损伤中的应用
US11807872B2 (en) 2019-08-27 2023-11-07 Wisconsin Alumni Research Foundation (Warf) Recombinant influenza viruses with stabilized HA for replication in eggs
CN112752251B (zh) * 2019-10-29 2022-05-06 中国移动通信有限公司研究院 一种ue标识符的分配方法、装置和计算机可读存储介质
CN115066610A (zh) * 2020-02-05 2022-09-16 住友制药株式会社 用于tau病变和痴呆相关疾病的确定试剂和确定方法
MX2022016322A (es) 2020-06-25 2023-01-24 Merck Sharp & Dohme Llc Anticuerpos de alta afinidad dirigidos a tau fosforilada en la serina 413.
EP4014997A1 (en) 2020-12-16 2022-06-22 Consejo Superior de Investigaciones Científicas (CSIC) Stard1 inhibitors for the treatment of lysosomal disorders
AU2021403010A1 (en) * 2020-12-16 2023-07-13 Voyager Therapeutics, Inc. Tau binding compounds
IL305666A (en) * 2021-03-18 2023-11-01 Seagen Inc Anti-ALPP/ALPPL2 antibodies and antibody-drug conjugates
WO2023092004A1 (en) 2021-11-17 2023-05-25 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
US5268164A (en) 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
US5112596A (en) 1990-04-23 1992-05-12 Alkermes, Inc. Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability
US6200768B1 (en) 1991-12-06 2001-03-13 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Method of screening for compounds that dissolve paired helical filaments
ATE191853T1 (de) 1992-07-27 2000-05-15 Us Health Zielgerichte liposome zur blut-hirne schranke
PT804584E (pt) 1994-10-21 2002-11-29 Innogenetics Nv Sequencias de virus da hepatite c genotipo 7 e sua utilizacao como agentes profilacticos terapeuticos e de diagnostico
US5756662A (en) 1995-03-14 1998-05-26 Corixa Corporation Compounds and methods for the detection of T. cruzi infection
WO1997034145A1 (fr) * 1996-03-13 1997-09-18 Mitsubishi Chemical Corporation Anticorps a proteine tau antiphosphorylee et procede de detection de la maladie d'alzheimer l'utilisant
WO1998022120A1 (en) * 1996-11-19 1998-05-28 The Wistar Institute Of Anatomy & Biology Diagnostic and therapeutic reagents for alzheimer's disease
JP2004503747A (ja) * 2000-07-11 2004-02-05 モレキュラー　ジェリアトリクス　コーポレイション 結合物質の同定するための試薬と方法
US6514221B2 (en) 2000-07-27 2003-02-04 Brigham And Women's Hospital, Inc. Blood-brain barrier opening
US20020065259A1 (en) 2000-08-30 2002-05-30 Schatzberg Alan F. Glucocorticoid blocking agents for increasing blood-brain barrier permeability
US7034036B2 (en) 2000-10-30 2006-04-25 Pain Therapeutics, Inc. Inhibitors of ABC drug transporters at the blood-brain barrier
US20030083299A1 (en) 2000-11-04 2003-05-01 Ferguson Ian A. Non-invasive delivery of polypeptides through the blood-brain barrier
DE10121982B4 (de) 2001-05-05 2008-01-24 Lts Lohmann Therapie-Systeme Ag Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung
EP2147679B1 (en) 2001-07-25 2014-06-25 Raptor Pharmaceutical, Inc. Compositions for blood-brain barrier transport
US20030162695A1 (en) 2002-02-27 2003-08-28 Schatzberg Alan F. Glucocorticoid blocking agents for increasing blood-brain barrier permeability
EP1581186A2 (en) 2002-12-03 2005-10-05 Blanchette Rockefeller Neurosciences Institute Artificial low-density lipoprotein carriers for transport of substances across the blood-brain barrier
KR20050101537A (ko) 2002-12-24 2005-10-24 뉴로켐 (인터내셔널) 리미티드 베타-아밀로이드 관련 질환의 치료를 위한 치료 제제
EP1663239A4 (en) 2003-09-10 2008-07-23 Cedars Sinai Medical Center KALIUM CHANNEL-MEDIATED FEEDING OF MEDICINES BY THE BLOOD BRAIN BARRIER
WO2005080986A1 (en) 2004-02-18 2005-09-01 University Of Iowa Research Foundation Antibodies to phosphorylated tau, methods of making and methods of use
EP2465872A3 (en) * 2004-10-25 2012-12-19 Merck Sharp & Dohme Corporation Anti-ADDL antibodies and uses thereof
US8012936B2 (en) * 2006-03-29 2011-09-06 New York University Tau fragments for immunotherapy
WO2008140639A2 (en) * 2007-02-08 2008-11-20 Oligomerix, Inc. Biomarkers and assays for alzheimer's disease
WO2008157302A2 (en) 2007-06-13 2008-12-24 Research Development Foundation Methods for treatment and prevention of tauopathies and amyloid beta amyloidosis by modulating crf receptor signaling
KR20100115340A (ko) 2007-10-19 2010-10-27 이무나스 파마 가부시키가이샤 Ａβ 올리고머에 특이적으로 결합하는 항체 및 그의 이용
CN102428101B (zh) * 2009-03-18 2016-03-02 Ac免疫有限公司 用于治疗用途的方法
UA107571C2 (xx) * 2009-04-03 2015-01-26 Фармацевтична композиція
CA3120504A1 (en) * 2009-06-10 2010-12-16 New York University Immunological targeting of pathological tau proteins
RU2518291C2 (ru) 2009-07-30 2014-06-10 Пфайзер Вэксинс ЭлЭлСи Антигенные tau-пептиды и их применения
JP6371526B2 (ja) * 2010-10-07 2018-08-08 エーシー イミューン エス．エー． タウを認識するリン酸化部位特異的抗体

Also Published As

Publication number Publication date
TW201216985A (en) 2012-05-01
WO2012045882A2 (en) 2012-04-12
IL225568A0 (en) 2013-06-27
SI2625198T1 (sl) 2015-11-30
MX2013003800A (es) 2013-06-28
ZA201302432B (en) 2016-07-27
ECSP13012609A (es) 2013-07-31
EP2625198A2 (en) 2013-08-14
SG189136A1 (en) 2013-05-31
ES2548686T3 (es) 2015-10-20
JP2014502141A (ja) 2014-01-30
CR20130160A (es) 2013-09-03
CA2812865C (en) 2021-01-26
HUE027649T2 (en) 2016-10-28
RU2013120544A (ru) 2014-11-20
US20120276009A1 (en) 2012-11-01
BR112013008333A2 (pt) 2021-09-21
CA2812865A1 (en) 2012-04-12
US9304138B2 (en) 2016-04-05
PE20140218A1 (es) 2014-03-01
AU2011311516B2 (en) 2015-06-11
KR20130115279A (ko) 2013-10-21
PL2625198T3 (pl) 2015-12-31
AU2011311516A1 (en) 2013-04-18
HK1187928A1 (zh) 2014-04-17
AR085198A1 (es) 2013-09-18
EP2987807A3 (en) 2016-06-01
US20160304590A1 (en) 2016-10-20
DK2625198T3 (en) 2015-09-28
RU2603078C2 (ru) 2016-11-20
EP2625198B1 (en) 2015-07-22
JP6371526B2 (ja) 2018-08-08
BR112013008333B1 (pt) 2022-10-11
WO2012045882A3 (en) 2012-05-31
MY164376A (en) 2017-12-15
KR101988672B1 (ko) 2019-06-12
CN103502272A (zh) 2014-01-08
IL225568A (en) 2017-06-29
CN103502272B (zh) 2016-06-15
EP2987807A2 (en) 2016-02-24
US10100104B2 (en) 2018-10-16
HK1216897A1 (zh) 2016-12-09
CL2013000951A1 (es) 2014-01-03
JP2017113004A (ja) 2017-06-29
MX338421B (es) 2016-04-15

Similar Documents

Publication Publication Date Title
CO6710903A2 (es) Un anticuerpo que reconoce y se une específicamente con un fosfo-epítope en la proteína tau de mamífero o en uno de sus fragmentos y una composición comprendiendo el mismo
AR092779A1 (es) Composicon farmaceutica que comprende anticuerpos que se unen a conformeros de proteinas tau
AR092818A1 (es) Anticuerpo tau humanizado
CY1123518T1 (el) Ανθρωπινα αντισωματα enanti-tau
CO2018014325A2 (es) Anticuerpos específicos para la tau hiperfosforilada y sus métodos de uso
ECSP11011367A (es) Composición farmacéutica
CL2011000010A1 (es) Anticuerpo monoclonal anti-peptido beta-amiloide; polinucleotido que lo codifica; hibridoma; metodo de produccion; composicion que lo comprende; uso para tratar enfermedades relacionadas con proteinas amiloides; metodo de diagnostico de las mismas; y kit que lo comprende.
BR112013008765B8 (pt) Anticorpos monoclonais anti-tau humano isolados ou um fragmento de ligação à tau dos mesmos, métodos de preparação dos mesmos, polinucleotídeo ou polinucleotídeos, vetor ou vetores, composição, método in vitro de diagnóstico ou monitoramento da progressão de uma tauopatia neurodegenerativa em um indivíduo humano, método in vitro para diagnosticar uma tauopatia neurodegenerativa em um indivíduo humano, e kit útil para o diagnóstico de uma tauopatia neurodegenerativa
MX2018008680A (es) Moleculas de union especifica a proteina de union a adn de respuesta transactiva de 43 kda (tdp-43).
GT201200271A (es) Proteínas que se unen al tnf-a
ECSP13012436A (es) ANTICUERPOS PEPTÍDICOS BETA AMILOIDE ANTI-N3pGlu Y USOS DE LOS MISMOS
EA201100923A1 (ru) Антитела человека против тканевого фактора
CR11374A (es) Proteinas humanas de union a antigenos del gm-csf
UA118332C2 (uk) Білок, що зв'язує антиген cd27l
PE20090329A1 (es) Anticuerpos humanizados contra el globulomero ab(20-42) y sus usos
EA201000238A1 (ru) Антигенсвязывающие белки для il-18 рецептора и их применение
AR067199A1 (es) Proteinas de union a antigenos que se unen a par-2
EA201590459A1 (ru) Специфические антитела к островковому амилоидному полипептиду человека (hiapp) и их применение
AR110114A1 (es) ANTICUERPOS CONTRA b-AMILOIDE PIROGLUTAMATO Y SUS USOS
CO6602134A2 (es) Proteinas de union a antigeno especificas para componente amiloide serico p
WO2017027685A3 (en) Antibody-based molecules specific for the truncated asp421 epitope of tau and their uses in the diagnosis and treatment of tauopathy
BR112014029089A2 (pt) anticorpo ou um fragmento de ligação de antígeno do mesmo; polinucleótido codificador; composto; composição/formulação farmacêutica; kit; uso; método in vitro para reduzir ou inibir a atividade da enzima tg2
BR112013023211A2 (pt) ensaio diagnóstico de anticorpos
CR20190012A (es) Anticuerpos específicos para la tauy hiperfosforilada y sus métodos de uso
EA202190387A1 (ru) Антитело к cd38 человека и его применение